Metastatic Carcinoma PDX Models

Suitable preclinical models such as patient-derived xenografts (PDX) are needed to evaluate drugs specifically targeting metastatic carcinoma. PDX models are known to be the most predictive preclinical model for evaluating an agent’s efficacy prior to entering the clinic. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. CrownBio’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER CANCER SUBTYPE # per page
MC0665 SCCCLICK TO VIEW
MC1392 NACLICK TO VIEW
MC1454 NACLICK TO VIEW
MC2296 NACLICK TO VIEW
MC3050 NACLICK TO VIEW
MC3084 NACLICK TO VIEW
MC3128 SCCCLICK TO VIEW
MC3160 SCCCLICK TO VIEW
MC3161 NACLICK TO VIEW
MC3359 AdenocarcinomaCLICK TO VIEW
MC3405 ADCCLICK TO VIEW
MC3464 SCCCLICK TO VIEW
MC3603 SCCCLICK TO VIEW
MC3624 ADCCLICK TO VIEW
MC3685 ADCCLICK TO VIEW
MC6624 NACLICK TO VIEW